The authors employed shRNA to downregulate cationic amino acid transporter-2 (CAT-2), which is involved in transmembrane transport of L-arginine into tumor cells, while this shRNA did not impact amino acid transporter-1 (CAT-1) on the surface of CD8+ T cells and macrophages. This evidence concerns the gene CD8A and neoplasm.